Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7605458 | 0.92 | FNTA (0.72) | FNTAFNTB | |
| SCHEMBL7605463 | 0.92 | FNTA (0.72) | FNTAFNTB | |
| SCHEMBL6777298 | 0.91 | FNTA (0.71) | FNTAFNTB | |
| SCHEMBL6777309 | 0.91 | FNTA (0.71) | FNTAFNTB | |
| Lithium Ion SCHEMBL7921395 | 0.90 | FNTA (0.59) | FNTAFNTB | |
| Lithium Ion SCHEMBL7916526 | 0.85 | FNTA (0.66) | FNTAFNTB | |
| Lithium Ion SCHEMBL6775179 | 0.85 | FNTA (0.69) | FNTAFNTB | |
| Lithium Ion SCHEMBL6781837 | 0.83 | FNTA (0.85) | FNTAFNTB | |
| Lithium Ion SCHEMBL7916446 | 0.83 | FNTA (0.60) | FNTAFNTB | |
| Lithium Ion SCHEMBL6773074 | 0.83 | FNTA (0.64) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | FNTA 20/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.